VECTICAL Drug Patent Profile

When do Vectical patents expire, and what generic alternatives are available?

Vectical is a drug marketed by Galderma Labs Lp and is included in one NDA.

The generic ingredient in VECTICAL is calcitriol. There are ten drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the calcitriol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vectical

A generic version of VECTICAL was approved as calcitriol by TEVA on October 12^th, 2001.

Summary for VECTICAL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	90
Clinical Trials:	4
Drug Prices:	Drug price information for VECTICAL
What excipients (inactive ingredients) are in VECTICAL?	VECTICAL excipients list
DailyMed Link:	VECTICAL at DailyMed

See drug prices for VECTICAL

Recent Clinical Trials for VECTICAL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Francisco	Phase 4
Galderma Laboratories	Phase 4
Emer, Jason, M.D.	Phase 4

See all VECTICAL clinical trials

Pharmacology for VECTICAL

Drug Class

Vitamin D3 Analog

US Patents and Regulatory Information for VECTICAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galderma Labs Lp	VECTICAL	calcitriol	OINTMENT;TOPICAL	022087-001	Jan 23, 2009		RX	Yes	Yes

Vectical Market Dynamics, Patent Estate, FDA Status and Financial Trajectory

Last updated: August 2, 2026

Vectical, a calcitriol 3 mcg/g ointment for mild-to-moderate plaque psoriasis in adults, was approved by the FDA in 2009 and commercialized by Galderma Laboratories. Its market was constrained by competition from generic topical corticosteroids, calcipotriene products, tazarotene, and combination therapies. Public filings do not disclose product-level Vectical revenue, and the product is listed as discontinued in U.S. commercial drug references. The commercial trajectory therefore appears to have progressed from niche launch to declining market presence and eventual withdrawal, with no identified active biosimilar or generic-entry event driving the outcome.

What is Vectical and what was its FDA status?

Vectical is the brand name for calcitriol ointment, 3 mcg/g. Calcitriol is the active form of vitamin D3 and acts through the vitamin D receptor to regulate keratinocyte proliferation and differentiation.

Attribute	Vectical
Active ingredient	Calcitriol
Strength	3 mcg/g
Dosage form	Topical ointment
FDA application	NDA 022419
Initial FDA approval	January 23, 2009
Indication	Mild-to-moderate plaque psoriasis in adults
Original sponsor/marketer	Galderma Laboratories, L.P.
FDA pathway	New drug application
Product category	Non-biologic prescription dermatology drug
Current U.S. commercial status	Discontinued in commercial drug references

The FDA-approved labeling limited Vectical to adults with mild-to-moderate plaque psoriasis. The product was not approved for pediatric use, systemic psoriasis, or other vitamin D-related indications.[1]

How did Vectical differ from calcipotriene?

Vectical used calcitriol rather than calcipotriene, another topical vitamin D analog. Both products target the vitamin D receptor pathway, but their chemical structures, labeling histories, formulation characteristics, and market positions differed.

Vectical’s clinical and commercial proposition was based on topical calcitriol delivery with a relatively low systemic exposure profile when used according to the label. Its practical disadvantages included ointment texture, limited indication breadth, and competition from lower-cost generic products.

When did Vectical lose exclusivity?

Vectical’s commercial exclusivity was primarily limited by the age of its active ingredient and the availability of competing topical psoriasis treatments. The product itself was approved in 2009, but calcitriol was not a new molecular entity. FDA approval did not create the type of long-duration market protection associated with a novel chemical entity.

The key exclusivity milestones were:

Event	Timing
FDA approval of Vectical	2009
Likely end of ordinary five-year NCE exclusivity	Not applicable because calcitriol was not a new molecular entity
Product patent protection	Dependent on listed formulation and composition patents
Commercial decline	Publicly evident before or around product discontinuation
Current status	No active branded growth platform identified

The United States grants five years of new chemical entity exclusivity only to qualifying products containing an active moiety that has not previously been approved. Calcitriol had prior regulatory history, so Vectical did not receive that protection.[2]

What patents protected Vectical?

Vectical’s protection was expected to depend on formulation, composition, and use claims rather than ownership of the calcitriol molecule itself. Calcitriol is an established active ingredient, which limits the value of molecule-level exclusivity.

Potential protection categories included:

1. Calcitriol ointment compositions.
2. Stabilized topical formulations.
3. Use of calcitriol for plaque psoriasis.
4. Manufacturing and packaging controls intended to preserve product stability.

The FDA Orange Book is the controlling public source for patents submitted by an NDA holder for use in an abbreviated new drug application certification. Patent listings can change over time, and historical listings may not remain visible in the same form after expiration or product discontinuation.[3]

No currently material, enforceable Vectical patent estate is identified in the cited public FDA materials. Any historical composition or formulation patent would have to be assessed against its expiration date, patent-term adjustment, terminal disclaimers, prosecution history, and claim scope. Because the active ingredient is old and the product has been discontinued, the remaining intellectual-property value is limited unless a separate formulation or manufacturing claim remains enforceable.

What formulations were protected by Vectical-related patents?

The commercially relevant formulation was a calcitriol ointment at 3 mcg/g. The principal value proposition was controlled topical delivery of a highly potent vitamin D analog in an ointment vehicle.

Formulation barriers were modest compared with those associated with complex biologics, liposomal products, inhaled devices, or transdermal systems. A competitor could potentially challenge a formulation patent through:

• Paragraph IV certification;
• An alternative excipient system;
• A non-infringing manufacturing process;
• A different topical dosage form;
• A 505(b)(2) application relying on published calcitriol data.

The product did not have the type of device or delivery-system complexity that typically supports a durable secondary patent estate.

What is the Orange Book status of Vectical?

Vectical was approved under NDA 022419. Orange Book relevance would have centered on any patents listed by the NDA holder against abbreviated applications for calcitriol ointment.

The commercial implications are:

• An Orange Book listing could have required an ANDA applicant to make a patent certification.
• A Paragraph IV certification could have triggered patent litigation and a potential 30-month stay.
• Expired or delisted patents would not provide continuing Orange Book leverage.
• Discontinuation of the reference product reduces the commercial incentive for an ANDA applicant, although it does not automatically eliminate regulatory pathways.

FDA regulations distinguish between drug products that are discontinued for commercial reasons and products withdrawn for safety or effectiveness reasons. The FDA’s discontinued-drug framework is therefore important when evaluating whether a discontinued reference product remains eligible for certain abbreviated approval strategies.[4]

Which companies challenged Vectical patents?

No material public Paragraph IV litigation against Vectical is identified in the cited FDA and publicly available product records. There is no established record here of a major generic manufacturer defeating a Vectical patent in federal court or entering a high-value settlement with Galderma.

The absence of a prominent Paragraph IV case is commercially significant. Vectical was a niche dermatology product with limited apparent revenue potential. A generic applicant may have determined that development, bioequivalence, formulation, and commercial-launch costs were not justified by the addressable market.

This does not mean that no ANDA filings or patent certifications ever existed. It means that no major, publicly documented patent dispute is identified in the sources used for this analysis.

What patent litigation affects Vectical?

No active, material Vectical patent litigation is identified in the cited public record.

The litigation risk profile is low for three reasons:

1. The active ingredient is established and not molecule-protected.
2. The product is commercially discontinued or no longer a significant branded product.
3. The market is crowded with alternative topical therapies.

Any residual risk would likely involve a narrow formulation claim rather than broad exclusion of all topical calcitriol products.

How did Vectical perform commercially?

Public financial statements do not provide audited, product-specific Vectical revenue, unit sales, gross margin, or operating income. Galderma was privately held for much of the product’s commercial life, which limited disclosure. Product-level sales were not separately reported in major public-company filings.

The financial trajectory can therefore be reconstructed directionally rather than through verified annual revenue:

Period	Commercial interpretation
2009-2011	Launch into prescription psoriasis market
2012-2015	Niche branded-product phase; competition from vitamin D analogs and steroids
2016 onward	Reduced commercial visibility and likely declining demand
Later period	Discontinued or commercially inactive U.S. brand

Vectical’s revenue ceiling was limited by its narrow indication and dosage form. Psoriasis treatment is a large therapeutic market, but topical calcitriol occupied a small segment within it. Most patients could be treated with generic topical corticosteroids, generic calcipotriene, combination products, or newer branded nonsteroidal therapies.

What factors reduced Vectical revenue?

The main revenue pressures were:

• Generic competition in topical psoriasis therapy.
• Limited physician differentiation from calcipotriene.
• Ointment vehicle preferences that reduced patient acceptance.
• Restrictions to adult mild-to-moderate plaque psoriasis.
• Payer pressure on branded dermatology products.
• Availability of topical corticosteroids at substantially lower cost.
• Lack of a broader lifecycle strategy based on new strengths, combinations, or delivery systems.

A product with a narrow label and no protected device generally requires sustained physician preference or strong payer access to maintain revenue. Vectical had neither a major platform franchise nor a broad indication expansion.

How does Vectical compare with competing psoriasis drugs?

Product or class	Active ingredient	Market position	Competitive effect on Vectical
Vectical	Calcitriol	Branded topical vitamin D analog	Reference product
Generic calcipotriene	Calcipotriene	Low-cost topical vitamin D analog	Direct substitute
Topical corticosteroids	Multiple agents	First-line and widely used	Strong price competition
Calcipotriene/betamethasone	Combination	Broad physician familiarity	Reduces need for single-agent vitamin D products
Tazarotene	Retinoid	Established topical option	Alternative mechanism
Tacrolimus/pimecrolimus	Calcineurin inhibitors	Used in selected inflammatory dermatoses	Indirect competition
Tapinarof	Nonsteroidal topical	Newer branded psoriasis treatment	Premium branded competition
Roflumilast	PDE-4 inhibitor	Newer topical anti-inflammatory	Expands nonsteroidal alternatives
Biologics	Multiple targets	Moderate-to-severe psoriasis	Indirectly reduces topical-only treatment for some patients

Vectical’s closest commercial competitors were calcipotriene and combination vitamin D analog/corticosteroid products. Newer nonsteroidal agents also weakened the rationale for retaining an older branded ointment.

What generic launch risks exist for Vectical?

The probability of a commercially meaningful generic launch appears low to moderate from a market perspective, even if regulatory approval were technically possible.

A generic applicant would face:

• Limited branded demand;
• Established alternatives;
• Potential formulation-comparability requirements;
• Low reimbursement opportunity;
• Limited promotional differentiation;
• Possible difficulty achieving adequate return on development costs.

The regulatory path could involve an ANDA if the product could demonstrate the required pharmaceutical equivalence and bioequivalence. A 505(b)(2) route could be considered where formulation or clinical bridging issues made a conventional ANDA less suitable. The appropriate pathway would depend on FDA product-specific guidance and the reference product’s regulatory status.[5]

A generic launch would not necessarily restore a large market. If Vectical’s branded demand had already contracted, generic entry could produce modest prescription volume but limited revenue.

Is there biosimilar risk for Vectical?

Vectical has no biosimilar risk because calcitriol ointment is a chemically synthesized small-molecule drug, not a biologic. The relevant competitive mechanisms are generic-drug substitution, 505(b)(2) development, therapeutic substitution, and competition from other topical psoriasis products.

This distinction matters for valuation. Biosimilar frameworks, biologic reference-product exclusivity, and interchangeability rules do not apply to Vectical.

Were there licensing deals involving Vectical?

No major publicly disclosed licensing transaction dedicated specifically to Vectical is identified in the cited record. Galderma’s role was associated with development and commercialization of the product, but the available FDA labeling does not establish a separate, high-value external licensing arrangement.

Vectical therefore does not appear to have generated a meaningful royalty stream or a transaction platform comparable with major dermatology franchises.

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers are limited relative to complex drug products. The principal requirements are:

• Control of calcitriol potency at microgram-level concentration;
• Protection against degradation;
• Homogeneous distribution in the ointment base;
• Stability through packaging and shelf life;
• Appropriate microbiological and chemical quality controls.

Calcitriol’s potency creates technical risks, but the product is not a sterile injectable, biologic, inhaled device, or complex controlled-release system. Manufacturing know-how may support product quality, but it is unlikely to create a durable barrier by itself after patent expiry.

Geographic protection was also limited. U.S. rights were tied to FDA approval, Orange Book listings, and U.S. patent law. Foreign rights would have depended on separate national or regional approvals, patent families, and local commercialization arrangements. No broad global Vectical franchise is evident from the public record.

What is the investment outlook for Vectical?

Vectical has little apparent standalone asset value. Its likely financial profile is:

• Low current branded revenue;
• No visible growth catalyst;
• Limited patent leverage;
• No biologic or device barrier;
• High substitution risk;
• Minimal probability of significant post-discontinuation revenue recovery.

The product could have residual value in a portfolio transaction involving dermatology assets, a generic development program, or a rights package in markets where topical calcitriol remains commercially available. That value would be based on regulatory files, manufacturing capability, or geographic rights rather than on U.S. branded sales growth.

Key Takeaways

• Vectical is calcitriol 3 mcg/g ointment, approved by the FDA in 2009 for adult mild-to-moderate plaque psoriasis.
• The product was a niche branded topical therapy competing with generic calcipotriene, corticosteroids, combination products, and newer nonsteroidal agents.
• Calcitriol’s prior approval history limited new-drug exclusivity.
• Vectical’s protection depended on formulation, composition, and use patents rather than active-ingredient exclusivity.
• No material active Vectical patent litigation or major Paragraph IV settlement is identified in the cited public record.
• Product-specific revenue was not publicly disclosed.
• Commercial status is discontinued or inactive in U.S. drug references, making current revenue exposure limited.
• Vectical has no biosimilar risk. Any competitive threat would come from generics, 505(b)(2) products, and therapeutic substitutes.
• The product’s remaining value is more likely to reside in regulatory, manufacturing, or non-U.S. rights than in U.S. branded growth.

FAQs

Was Vectical a steroid?

No. Vectical contained calcitriol, a topical vitamin D analog. It was not a corticosteroid.

Can a generic manufacturer still develop calcitriol ointment?

Potentially. The applicable pathway would depend on FDA reference-product status, formulation equivalence, bioequivalence requirements, and any remaining patent or regulatory barriers.

Did Vectical receive FDA pediatric exclusivity?

No pediatric exclusivity is identified in the cited FDA product record.

Is Vectical interchangeable with calcipotriene?

No automatic interchangeability should be assumed. Calcitriol and calcipotriene are different active ingredients and require separate regulatory determinations.

Does Vectical have residual value outside the United States?

Potentially, but value would depend on country-specific approvals, patent status, distribution rights, and local demand. The available U.S. record does not establish a material global revenue stream.

References

1. U.S. Food and Drug Administration. (2009). Vectical (calcitriol) ointment, 3 mcg/g: Prescribing information. Galderma Laboratories, L.P.

2. U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Patent and exclusivity information. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). Discontinued drug product list. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process and 505(b)(2) applications. Center for Drug Evaluation and Research.

DrugChatter Q&A for VECTICAL

How does vectical treat psoriasis?